Transition From Intravenous to Subcutaneous Insulin in Critically Ill Adults
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Glycemic control decreases morbidity and mortality in critically ill patients. However, limited guidance exists regarding the transition from intravenous (IV) to subcutaneous insulin therapy. A validated protocol for transition is necessary since glycemic variability, hyperglycemia, and hypoglycemia adversely impact patient outcomes. Method: The objective was to determine the safest and most effective method to transition critically ill adults from IV to subcutaneous insulin. This single-center, retrospective, observational study included adults admitted to the burn, medical, or surgical/trauma intensive care units from January 1, 2011, to September 30, 2014. A computer-based program provided a reflection of the patient’s total daily IV insulin requirements. This information was then utilized to stratify patients into groups according to their initial dose of subcutaneous insulin as a percentage of the prior 24-hour IV requirements (group stratification: 0-49%, 50-59%, 60-69%, 70-79%, ≥80%). The primary endpoint was the percentage of blood glucose (BG) concentrations within target range (70-150 mg/dL) 48 hours following transition. Results: One hundred patients with 1394 BG concentrations were included. The 50-59% group achieved the highest rate of BG concentrations in goal range (68%) ( P < .001). The 0-49% group, which was the transition method utilized most often, resulted in the lowest rate of goal achievement (46%). Conclusions: This retrospective study suggests critically ill adults may be safely transitioned to 50-59% of their 24-hour IV insulin requirements. A dosing protocol will be implemented to transition to 50-70% subcutaneous insulin. Follow-up data will be reviewed to assess the protocol’s safety and efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While the use of these agents is safe and may result in lower glucose levels and insulin doses, we do not recommend addition of a DPP-4 inhibitor or GLP-1 RA to IV insulin therapy until efficacy is demonstrated.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1317]
In the citing paper
“The addition of noninsulin agents, such as DPP-4 inhibitors or GLP-1 RAs, before admission or during the perioperative period, has not reduced rates of stress hyperglycemia and may increase nausea and vomiting rates1316–1324 among critically ill persons.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1317]
Citations
Cites
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 2×
“The mechanism of harm includes oxidative stress, neuronal damage, mitochondrial damage, and coagulation activation.(14-17) However, the most appropriate metric to describe glucose variability has not yet been defined.”
BackgroundIntensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Intensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Capes, S. E., Hunt, D., Malmberg, K., & Gerstein, H. C. (2000) · The Lancet · doi:10.1016/s0140-6736(99)08415-9 · Cited by 2,187 · cited 3×
“While glycemic control has been shown to decrease morbidity and mortality, conflicting data exists regarding the optimal target range for blood glucose (BG) in critically ill adu lts.(1-5,7-9) Due to conflicting results in the literature, professional organizations such as the Society of Critical Care Medicine (SCCM)…”
BackgroundDungan, K. M., Braithwaite, S. S., & Preiser, J.-C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60553-5 · Cited by 1,431
Krinsley, J. S. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.12.1471 · Cited by 1,165 · cited 3×
“While glycemic control has been shown to decrease morbidity and mortality, conflicting data exists regarding the optimal target range for blood glucose (BG) in critically ill adu lts.(1-5,7-9) Due to conflicting results in the literature, professional organizations such as the Society of Critical Care Medicine (SCCM)…”
BackgroundVariability of Blood Glucose Concentration and Short-term Mortality in Critically Ill Patients
Egi, M., Bellomo, R., Stachowski, E., French, C. J., & Hart, G. (2006) · Anesthesiology · doi:10.1097/00000542-200608000-00006 · Cited by 854 · cited 4×
“Glucose variability has been independently associated with short-term ICU mortality.(14-16) The mechanism of harm includes oxidative stress, neuronal damage, mitochondrial damage, and coagulation activation.”
BackgroundInfluentialJacobi, J., Bircher, N., Krinsley, J., Agus, M., Braithwaite, S. S., Deutschman, C., Freire, A. X., Geehan, D., Kohl, B., Nasraway, S. A., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182653269 · Cited by 571 · cited 6×
“The guidelines also suggest glucose variability may be a better end point to assess the impact of BG on patient outcome.(10) Glucose variability has been independently associated with short-term ICU mortality.”
BackgroundMethodInfluentialGlucose variability is associated with intensive care unit mortality*
Hermanides, J., Vriesendorp, T. M., Bosman, R. J., Zandstra, D. F., Hoekstra, J. B., & DeVries, J. H. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cc4be9 · Cited by 437 · cited 4×
“Glucose variability has been independently associated with short-term ICU mortality.(14-16) The mechanism of harm includes oxidative stress, neuronal damage, mitochondrial damage, and coagulation activation.”
BackgroundInfluential
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Clinical challenges of glycemic control in the intensive care unit: A narrative review
Sreedharan, R., Martini, A., Das, G., Aftab, N., Khanna, S. K., & Ruetzler, K. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i31.11260 · Cited by 26
Insulin Therapy for Hyperglycemia Management in Critically Ill Patients
Eastman, D. K., Butler, J., Dicken, S., & Bottenberg, M. M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115025 · Cited by 6
Development of insulin and its pharmacology and perioperative use: a narrative review
Dhatariya, K., Levy, N., Stubbs, D. J., Frank, C., Tinsley, S. L., & Knaggs, R. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.006 · Cited by 8
Transitioning from intravenous to subcutaneous insulin in the medical intensive care unit
Zhou, K., Williams, M. F., Esquivel, M. A., Song, A., Rahman, F., Bena, J., Lam, S. W., Rathz, D. A., & Lansang, M. C. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.016 · Cited by 6
Metadata
- Authors
- Doolin, M. K., Walroth, T. A., Harris, S. A., Whitten, J. A., & Fritschle-Hilliard, A. C.
- Affiliations
- Eskenazi Health (US)
- Eskenazi Health, Department of Pharmacy, Indianapolis, IN, USA
- Corresponding author
- Doolin, Meagan K.
- ORCID
- Walroth, Todd A.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2016-02-23
- Volume
- 10
- Issue
- 4
- Pages
- 932-938
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC4928222
- OpenAlex
- W2302681494
- Cited by
- 13
- References
- 17
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 3 · 2017: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Keywords
- intravenous insulin, subcutaneous insulin, critically ill adults, glycemic control, blood glucose, intensive care, hyperglycemia, hypoglycemia
- MeSH terms
- Adult, Aged, Blood Glucose, Critical Care, Female, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Infusions, Intravenous, Injections, Subcutaneous, Insulin, Male, Middle Aged, Retrospective Studies, Critical Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transition From Intravenous to Subcutaneous Insulin in Critically Ill Adults. https://app.cochat.ai/papers/10.1177/1932296816629985
- The paper
- Doolin, M. K., Walroth, T. A., Harris, S. A., Whitten, J. A., & Fritschle-Hilliard, A. C. (2016). Transition From Intravenous to Subcutaneous Insulin in Critically Ill Adults. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296816629985
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.